First AD

Second AD

Panelists discuss how emerging areas in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) research include novel immunotherapy combinations, biomarker development for treatment selection, targeted therapies against new molecular pathways, and strategies to overcome resistance to existing treatments.

Future Considerations for the Treatment of R/M HPV-Positive HNSCC

Video content above is prompted by the following:

What areas for future research in the treatment of R/M HNSCC should clinicians keep an eye on?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Exploring the Role of a Novel HPV16-Targeted Cancer T-cell Stimulating Immunotherapy (TSI) (Versamune® HPV) for Human Papilloma Virus (HPV) Positive Head and Neck Cancer (HNSCC)